Source: BioTechniques, by Maddy Chapman (September 1, 2026). AI-generated summary by biochip.com, published . Not independently reviewed.
Key takeaways
- MGI Tech announced the European launch of VisiOmics, a fully automated multiplex immunofluorescence staining and imaging system.
- The company introduced VisiOmics at the European Congress of Pathology in Stockholm, held September 12 through 16.
- The announcement provides no performance data, technical specifications, or clinical validation for VisiOmics.
MGI Tech has announced the European launch of VisiOmics, a fully automated system for multiplex immunofluorescence staining and imaging. The company introduced the platform at the European Congress of Pathology in Stockholm, Sweden, held September 12 through 16. Multiplex immunofluorescence is a technique that uses fluorescent labels to make several biological targets visible in the same specimen. Instead of examining one signal at a time, researchers can build up a more detailed picture from multiple labeled features within tissue. Automation matters because staining and image collection involve many repeated steps that can be difficult to perform consistently by hand. VisiOmics is one element of a broader biotech update that also flags a human genome database, metabolomics technology, artificial intelligence partnerships in antibody discovery, and funding for rapid molecular testing. The announcement is therefore a product launch rather than a report of clinical performance or a completed research study.
What Multiplex Immunofluorescence Does
Immunofluorescence works somewhat like placing colored sticky notes on selected parts of a complex map. Antibodies bind to particular molecular targets in a biological sample, while fluorescent markers allow those targets to be seen under an imaging system.
The word multiplex means that the process is designed to look at more than one target. In tissue research and pathology, that can help investigators examine how different features appear in relation to one another within the same sample rather than splitting the analysis across separate slides.
An Automated Staining and Imaging System
MGI Tech describes VisiOmics as a fully automated multiplex immunofluorescence staining and imaging system. The designation joins two parts of the workflow: preparing a specimen with fluorescent stains and capturing images of the resulting signals.
That integration can be important in a technique with repeated staining, imaging, and analysis steps. Like a camera that follows a programmed sequence rather than requiring a photographer to reset every control manually, an automated platform is intended to carry out a defined process in a consistent order.
European Launch in Stockholm
MGI Tech announced the European launch at the European Congress of Pathology in Stockholm. The meeting was held from September 12 to 16, giving pathology-focused attendees a setting in which to encounter the system.
The supplied announcement identifies Shenzhen, China, as MGI Tech's location and characterizes the company as a developer of core life-science tools and technologies. It does not provide technical specifications for VisiOmics, comparisons with other systems, or data showing how the platform performs in clinical settings.
A Wider Biotech Update
The biotech roundup places the VisiOmics launch alongside several other developments. These include datasets intended to deepen understanding of the human genome, a metabolomics kit, partnerships connecting artificial intelligence with antibody discovery, and funding related to rapid molecular testing.
Those topics represent distinct parts of modern life science. A genome database organizes genetic information, metabolomics examines small molecules involved in biological activity, and molecular testing looks for biological signals such as nucleic acids. The update does not establish a direct technical link between those items and the VisiOmics platform.
Why This Matters
Multiplex staining and imaging are closely tied to biological sensing because they turn molecular recognition into visual data. The sensing event begins when an antibody recognizes its intended target, and fluorescence provides a detectable signal that can be recorded as an image.
A platform that automates this sequence could be relevant to laboratories seeking a more standardized route from stained tissue to image collection. Still, a launch announcement alone cannot show whether the system improves accuracy, throughput, ease of use, or reproducibility compared with existing multiplex immunofluorescence workflows.
What Comes Next
The important next questions concern how VisiOmics performs across real sample types and how laboratories use its automated workflow in practice. Independent performance data, details on the number of markers supported, and evidence from pathology applications would help clarify the platform's role in multiplex biological imaging.